Delhi High Court Rejects Zydus Healthcare's Challenge to Helsinn's Pharmaceutical Patent Grant

Introduction

In a significant ruling for pharmaceutical patent litigation in India, the Delhi High Court on December 24, 2025, dismissed a writ petition filed by Zydus Healthcare Ltd. challenging the grant of Patent No. 426553 to Swiss drugmaker Helsinn Healthcare SA. The patent covers compositions and methods for treating centrally mediated nausea and vomiting using a combination of palonosetron and netupitant. Justice Tejas Karia, in a detailed judgment, held that the Delhi High Court lacked territorial jurisdiction since the patent was granted by the Mumbai Patent Office. Furthermore, the court found no manifest jurisdictional error in the Patent Office's proceedings, emphasizing the separation between pre-grant opposition and patent examination processes. This decision reinforces procedural boundaries in patent prosecution and limits the scope of writ jurisdiction in such matters, potentially streamlining patent grants while protecting innovators in the competitive pharmaceutical sector.

The case, titled Zydus Healthcare Ltd. v. Assistant Controller of Patents and Designs & Anr. (W.P.(C)-IPD 23/2023), underscores the Patents Act, 1970's framework for oppositions and amendments, particularly under Sections 14, 25(1), 57, and 59. It arrives amid ongoing debates on patent evergreening and access to affordable medicines, where generic players like Zydus often challenge originator patents to enter the market sooner.

Case Background

The dispute originates from Helsinn's patent application No. 1009/MUMNP/2012, filed on April 20, 2012, via the Patent Cooperation Treaty (PCT) route, entering the Indian national phase. The application initially featured 51 claims, including five independent ones, focused on an orally administered dosage form combining palonosetron (a 5-HT3 receptor antagonist) and netupitant (an NK1 receptor antagonist) for treating chemotherapy-induced nausea and vomiting (CINV). This combination addresses both acute and delayed phases of emesis, a critical need in oncology care.

Zydus Healthcare Ltd., a subsidiary of Zydus Lifesciences Limited and a major player in generic pharmaceuticals, emerged as an opponent. The timeline unfolded as follows:

• July 25, 2013 : Helsinn filed its first voluntary amendment under Section 57 of the Patents Act, reducing claims from 51 to 14. This "First Amendment" deleted claims 1-33, renumbered original claim 34 as the new claim 1 (focusing on dosage specifics: about 0.56 mg palonosetron hydrochloride and 200-400 mg netupitant), and aimed to clarify the invention by converting method-of-treatment claims to pharmaceutical composition claims.

• September 21, 2017 : The Patent Office (Mumbai) issued the First Examination Report (FER), objecting to novelty, inventive step, and compliance with Sections 3(d) and 3(e) (prohibiting patents on mere admixtures without enhanced efficacy).

• March 19, 2018 : Helsinn responded with a "Second Amendment," further refining claims to 11, with two independent claims. Another opponent, M/s. Panacea Biotec Ltd., filed a representation in June 2018 but did not pursue it.

• September 6, 2021 : Zydus filed a pre-grant opposition under Section 25(1), alleging the amendments broadened claim scope impermissibly, violated Section 59 (amendments must not exceed original disclosure), and lacked support in the complete specification. Zydus argued the specification only supported embodiments with dosages outside the claimed range or including a third agent (dexamethasone), rendering the claims invalid under Section 3(e) for non-synergistic admixtures.

• May 20, 2022 : A hearing (Hearing I) was held on the opposition, with Zydus submitting written arguments on July 4, 2022. The Controller reserved the order.

• February 17, 2023 : Post-reservation, the Controller issued a hearing notice under Section 14 solely to Helsinn, citing further objections.

• March 3, 2023 : Helsinn made a "Third Amendment" in response, deleting certain claims and making others dependent (e.g., re-numbering claim 7 as claim 5 dependent on claim 1). No hearing opportunity was given to Zydus at this stage (Hearing II).

• March 23, 2023 : The Controller rejected Zydus's opposition, accepted the amendments, and granted the patent.

Zydus then approached the Delhi High Court via writ petition under Article 226, claiming jurisdictional errors, violation of natural justice (no hearing on third amendment), and non-compliance with amendment procedures. The legal questions centered on: (1) territorial jurisdiction; (2) availability of alternative remedies; (3) necessity of a separate order on pre-FER amendments; and (4) right to hearing in the examination process post-opposition hearing.

This backdrop highlights tensions in India's patent regime, balancing innovation incentives for originators like Helsinn with generic competition from firms like Zydus, especially for high-value anti-emetic drugs used in cancer treatment.

Arguments Presented

Zydus, represented by Senior Advocate Dayan Krishnan and a team including Adarsh Ramanujan, mounted a multi-pronged attack, asserting procedural lapses amounting to jurisdictional errors warranting writ intervention.

Petitioner's Contentions: - Amendments and Section 59 Violation : Zydus argued the First Amendment impermissibly broadened scope by deleting limitations (e.g., "outer shell," specific impurity limits) without a separate determination order under Sections 57 and 59 read with Rule 81(2). Citing Ashok Leyland Ltd. v. State of T.N. (2004) 3 SCC 1, they claimed "determination" requires a speaking order applying mind, not mere FER acceptance. The complete specification lacked support for dexamethasone-free claims, violating Section 59 ( Allergan Inc. v. Controller of Patents , 2023 SCC OnLine Del 295). Subsequent amendments perpetuated this error.

• Natural Justice Breach : Post-Hearing I reservation, the unilateral Hearing II under Section 14 denied Zydus a chance to oppose the Third Amendment, violating audi alteram partem. Invoking Natco Pharma Ltd. v. Union of India (2022:DHC:2632), they urged notice to pre-grant opponents in Section 14 hearings.

• Jurisdiction and Maintainability : Despite Mumbai's grant, Delhi HC had jurisdiction under Article 226(2) due to "dynamic effects" ( Dr. Reddy's Laboratories Ltd. v. Controller of Patents , 2022 SCC OnLine Del 3747), as Zydus's commercial interests (manufacturing/sales) are in Delhi. No efficacious alternative remedy existed, as Section 117A appeals exclude pre-grant rejections, and writs lie for natural justice violations ( Whirlpool Corp. v. Registrar of Trademarks , (1998) 8 SCC 1). Grounds like Section 59 breaches aren't appealable but challengeable via writ.

• Merits : Claims violated Sections 3(d)/(e) for lacking enhanced efficacy/synergy; specification enabled only non-claimed embodiments.

Respondents' Contentions: The Assistant Controller (Respondent No. 1), represented by Vikrant N. Goyal et al., and Helsinn (Respondent No. 2), by Senior Advocate Amit Sibal and Pravin Anand, defended the process rigorously.

• Jurisdictional Objection : Proceedings occurred entirely in Mumbai, the "appropriate office" under Rule 4(2). Writ jurisdiction mirrors Section 117A appeals, vesting only in the High Court of the patent office's location ( Filo Edtech Inc. v. Union of India , 2023 SCC OnLine Del 7304; Dr. Reddy’s Laboratories supra, distinguishing revocation suits). Forum non conveniens applied.

• Alternative Remedies : Pre-grant failure allows post-grant opposition (Section 25(2)) or revocation (Section 64) ( Novartis AG v. Natco Pharma Ltd. , 2024 SCC OnLine Del 152; Rich Products v. Controller of Patents , 2024 SCC OnLine Del 3144). Section 117A covers orders under Sections 15/57; review under Section 77(1)(f) or revocation for fraudulent amendments (Section 64(o)) available. Writs are discretionary, not for merits review absent jurisdictional error ( UCB Farchim SA v. Cipla Ltd. , 2010 SCC OnLine Del 523; Glochem Industries Ltd. v. Cadila Healthcare Ltd. , 2009 SCC OnLine Bom 1701).

• Amendments Valid : No separate pre-FER order needed; FER itself determines amendments (continuous examination). Amendments narrowed scope, supported by specification (e.g., Example 5 shows synergy). Section 25(1) excludes amendment challenges; proper forum is revocation.

• No Natural Justice Violation : Pre-grant opposition (Section 25(1)/Rule 55) and examination (Section 14) are distinct; opponents lack hearing rights in examination ( Novartis AG supra). Hearing I addressed Zydus's grounds; documents uploaded publicly. Third Amendment was minor (deletions/dependencies), not substantive under Section 57(3).

• Merits Defense : No Section 3(d)/(e) bar; no prior art for "known substance"; synergy proven. Zydus's counterclaim in Helsinn's infringement suit (CS(COMM) 629/2023) overlaps, risking conflicting judgments.

These arguments framed the petition as an attempted merits appeal disguised as jurisdictional challenge, which the court scrutinized closely.

Legal Analysis

Justice Karia's 60-paragraph judgment methodically dissects the issues, drawing on precedents to affirm procedural integrity while curtailing writ overreach. The court's reasoning pivots on statutory interpretation, emphasizing the Patents Act's intent for expeditious grants (Section 43(1)) without undue external interference.

Territorial Jurisdiction : Rejecting Zydus's "dynamic effect" plea ( Dr. Reddy’s Laboratories (2022)), the court distinguished revocation petitions (Section 64, where commercial impact confers jurisdiction) from writs/appeals challenging Patent Office orders (Section 117A). Writs under Article 226 analogize to appeals, vesting jurisdiction solely in the High Court of the "appropriate office" (Mumbai). Filo Edtech (2023) reinforced this, preventing forum-shopping. No "cause of action" arose in Delhi; the petition was non-maintainable ab initio.

Alternative Remedies and Writ Discretion : Even absent jurisdiction, the court noted writs are extraordinary, exercisable only for "manifest jurisdictional error" ( Rich Products (2024); UCB Farchim (2010); Glochem (2009)). Pre-grant opponents have robust remedies: post-grant opposition (Section 25(2)), revocation (Section 64, including for amendments via fraud under 64(o)), or review (Section 77). Zydus's overlap with its infringement counterclaim further militated against writ entertainment, avoiding multiplicity ( Dr. Reddy’s Laboratories v. Fast Cure Pharma , 2023:DHC:6324).

Pre-FER Amendments and Section 57/59 : No statutory mandate for a separate speaking order on voluntary pre-FER amendments; the FER itself constitutes "determination" under Rule 81(2), as examination is continuous. Natco Pharma (2022) urged brief orders for post-FER amendments, but pre-FER ones integrate into FER review. Zydus waived objection by not raising it timely in opposition. On merits, writs bar substantive review ( Rich Products ); specification support and scope-narrowing validated amendments, not broadening as alleged.

Natural Justice and Process Separation : Core to the ruling, the court upheld Novartis AG (2024)'s dichotomy: pre-grant opposition (Section 25(1)/Rule 55) invites external inputs on specified grounds (exhaustive, excluding amendments), while examination (Section 14) is Controller-centric for compliance. Rule 55(5)'s "hearing" confines to opposition adjudication; no opponent right in examination ( Novartis AG , paras 86-97). Section 57(6) exempts Controller-directed amendments from opposition rigors. Hearing I sufficed; public uploads (Hearing Notice, submissions) allowed Zydus input via misc. petition ( Dr. Snehlata C. Gupte v. Union of India , 2010 SCC OnLine Del 2374). Merging processes would delay grants, contra legislative policy. Third Amendment's minor nature (deletions) didn't trigger notice.

Distinctions clarified: Opposition aids but doesn't bind examination; opponent rights pivot to Section 25(1) grounds only. No Section 3(d)/(e) merits dive, deferred to pending suit.

This analysis aligns with India's TRIPS-compliant regime, prioritizing efficiency while safeguarding fairness.

Key Observations

The judgment extracts pivotal insights, emphasizing procedural autonomy:

• On process separation: “The right of hearing of the opponent under Rule 55 of the Rules is confined to a consideration of issues raised in the Pre-Grant Opposition. The two processes are separate from each other as the examination process demands a focused evaluation of the application while the opposition process is to address the concerns of external stakeholders.” (Para 60(e))

• On writ limits: “A review on merits involving disputed questions of fact is not permissible while exercising the writ jurisdiction under Article 226 of the Constitution in absence of any jurisdictional error committed by the learned Controller.” (Para 44)

• Legislative balance: “To merge the process would be to compromise the rigors of examination, since external inputs, though valuable, are best considered within the distinct and specific framework of the opposition. Merging these distinct processes would render the entire system unwieldy and counterproductive quite apart from negatively impacting the legislative policy of expeditious consideration.” (Quoting Novartis AG , Para 58)

• Jurisdiction rationale: “In the case of appeals where challenges against orders of the Patent Office are raised the concept of cause of action cannot be pleaded to vest jurisdiction in other High Courts i.e. other than the one in the territorial jurisdiction of which the appropriate office is located.” (Para 20, citing Dr. Reddy’s Laboratories )

• Amendment determination: “As the First Amendment was duly considered by Respondent No. 1 in FER, the Act and Rules do not contemplate the two-step procedure for issuance of a formal order in cases where the applicant has made amendments voluntarily prior to the issuance of FER.” (Para 39)

These observations distill the ruling's essence, guiding future Patent Office practice and litigants.

Court's Decision

The Delhi High Court dismissed the writ petition, upholding the patent grant without costs. No interference was warranted due to lack of jurisdiction and absence of jurisdictional errors. The impugned order dated March 23, 2023, stands affirmed.

Implications : This decision fortifies the Mumbai Patent Office's autonomy and delimits Delhi HC's writ role, potentially centralizing challenges to that forum. It clarifies no separate pre-FER amendment orders needed, easing prosecution for applicants like Helsinn while pressuring opponents to exhaust statutory remedies (post-grant/revocation). For pharmaceuticals, it shields combination drug patents from procedural overreach, aiding anti-emetic innovations amid rising cancer cases. Generics like Zydus must pivot to revocation or countersuits, risking delays/costs.

Broader effects: Reinforces Novartis AG 's separation doctrine, reducing opposition leverage in examination and promoting efficiency (20-month grant timeline here). Future cases may see fewer writs, fewer delays, but increased post-grant scrutiny. Amid India's generic dominance (20% global share), it balances TRIPS obligations with Section 3 safeguards against evergreening. Helsinn's pending injunctions against rivals (e.g., Hetero, AET Labs) may proceed unhindered, impacting CINV market access.

In sum, the ruling streamlines patenting, urging stakeholders toward statutory channels over extraordinary relief.